LGALS3BP is suspected to be a tumor suppressor due to its under-expression in prostate cancer, while CSNK2A2 over-expression promotes tumor progression, particularly in hepatocellular carcinoma [50]. Here, LGALS3BP is linked to prostate carcinoma.